Search
Menu
Home
HTB
2000
December
HTB
December 2000
Contents
Conference reports
Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK
Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy
When should HAART be started?
MDR resistance transmission increases in the UK
Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis
Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)
Clinical issues arising from a single treatment interruption
A review of new anti-HIV drugs in development
Antiretroviral therapy in children, women and intravenous drug users
Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial
Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients
Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART
Child protection issues around starting efavirenz in a mother on maintenance methadone
Structured treatment interruptions
Adherence and HAART: unique approaches to evaluating and improving adherence discussed
Reports on lipodystrophy and metabolic complications
Opportunistic infections in the HAART era
Antiretrovirals
Importance of intensive adherence support for people with HIV-related neurological symptoms
Efavirenz side effects become long-term for over one in three
ABT-378/r oral formulation available in UK
Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor
Women's health
Women initiate highly active antiretroviral therapy later than men
Association of vitamin A deficiency With cervical squamous intraepithelial lesions in HIV-positive women
Side effects
Adverse effects of antiretroviral therapy
Basic science and immunology
Antiretrovirals do not independently affect T-cell count in HIV negative subjects
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells
HLA-DR integrates with HIV-1 at chronic disease stage, may raise infectivity
Vaccines and microbicides
Immune Response Corporation tried to block report on failure of Remune
Other news
FDA meeting on approving immune therapies: background and comment
HIV seroprevalence by anonymous testing in patients with mycobacterium tuberculosis and in tuberculosis contacts
HIV-1 Immunogen fails to extend HIV progression-free survival
On the web
AIDS-related lymphoma
PDFs
Volume 1 Number 8 November / December 2000 PDF
HTB RSS
Early access
EACS guidelines: New format and contents includes chemsex
21 November 2024
Future PrEP and new results from PURPOSE 1 and 2: does HIV exposure explain incident cases?
21 November 2024
Glasgow HIV Congress 2024
10 November 2024
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate